| abstract |
The present invention provides an isolated polypeptide comprising or consisting of an amino acid sequence according to SEQ ID NO: 1 (AS 136-154) (EEAEKAKEAAEKALNEAFE) or an amino acid sequence having a sequence identity of at least 70. %, preferably at least 80%, more preferably at least 90% to SEQ ID NO 1, the polypeptide having a maximum length of 200, preferably a maximum length of 170 amino acids. The invention provides a nucleic acid encoding said polypeptide, a gene therapy vector comprising said nucleic acid, and genetically modified cells expressing said polypeptide. The invention further relates to the medical use of said polypeptide, said nucleic acid, said gene therapy vector and / or said cell in the treatment of a disease associated with long-lived pathogenic plasma cells. |